Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage
09 Noviembre 2023 - 7:32AM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing, and marketing
products that improve the quality of life for patients who suffer
from neurohealth disorders, today announced healthcare policy
updates from Magellan, BlueCross BlueShield (BCBS) of
Kansas City, and Dean Health Plan that increase access
for patients to the Company’s NeuroStar® Advanced Therapy.
Criteria changes from all three providers reduce the number of
prior antidepressant medication failures from four down to two
before a patient is eligible to receive coverage for transcranial
magnetic stimulation (TMS) therapy for major depressive disorder
(MDD). Dean Health Plan has also removed the requirement for a
prior trial of psychotherapy. The policy updates from BCBS Kansas
City and Dean Health Plan are effective immediately, with the
Magellan update going into effect on November 18, 2023.
“It’s heartening to see this inflection point for increased
access to mental health coverage,” stated Keith J. Sullivan,
President, and CEO of Neuronetics Inc. “Reducing barriers and
allowing people to receive proven treatments like NeuroStar TMS
earlier in their care plan is a significant way payors can help
alleviate the mental health crisis.”
Magellan is one of the largest behavioral health plans in the
country, with numerous commercial payors contracting their
services. Their health plans impact 2.4 million covered lives in
AL, AZ, CA, CO, DC, FL, HI, IL, MD, MI, NC, NJ, NM, OH, OR, PA, SC,
TN, TX, and WY. BCBS Kansas City policies cover over 600,000 lives
in MO and KS. Dean Health Plan represents nearly 609,000 covered
lives in IL, MO, and WI.
Neuronetics previously announced updated policies through payers
such as Aetna, BlueCross BlueShield of Michigan,
and United HealthCare. Neuronetics is the only TMS company in
the industry with a dedicated health policy team that partners with
both providers and payors to advocate for health policy
changes.
Major depressive disorder (MDD) is a serious issue that affects
21 million adults in the United States, with 6.4 million people
being underserved by antidepressant medication. NeuroStar TMS is a
non-drug treatment that can help alleviate the burden of
drug-resistant depression. For more information about NeuroStar TMS
Therapy, please visit NeuroStar.com.
About NeuroneticsNeuronetics,
Inc. believes that mental health is as important as physical
health. As a global leader in neuroscience, Neuronetics is
redefining patient and physician expectations with its NeuroStar
Advanced Therapy for Mental Health. NeuroStar is a non-drug,
noninvasive treatment that can improve the quality of life for
people suffering from neurohealth conditions when traditional
medication hasn’t helped. NeuroStar is FDA-cleared for adults with
major depressive disorder (MDD), as an adjunct for adults with
obsessive-compulsive disorder (OCD), and to decrease anxiety
symptoms in adult patients with MDD that may exhibit comorbid
anxiety symptoms (anxious depression). NeuroStar Advanced Therapy
is the leading transcranial magnetic stimulation (TMS) treatment
for MDD in adults with over 5.9 million treatments delivered.
NeuroStar is backed by the largest clinical data set of any TMS
system for depression, including the world’s largest depression
Outcomes Registry. Neuronetics is committed to transforming lives
by offering an exceptional treatment that produces extraordinary
results. For safety and prescribing information,
www.neurostar.com.
Media
Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
Neuronetics (NASDAQ:STIM)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Neuronetics (NASDAQ:STIM)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024